Eurofins Scient. Stock: Shares Fall Further by 2%, Oddo BHF Lowers Target
The Luxembourg-based bioanalytical testing specialist is among the most penalized stocks in the CAC 40 this Thursday noon. The stock suffers a new weakness as Oddo BHF lowered its price target the day before. The analyst's note weighs on a stock already weakened by poorly received April quarterly results.
Oddo BHF Lowers Target to €67 While Maintaining Neutral Rating
Eurofins Scientific shares are down 2.11% at €61.14, among the steepest declines in the CAC 40, while the Paris index is down 0.48%. The movement comes after Oddo BHF revised its price target from €70 to €67 while maintaining a neutral opinion. The new target implies a theoretical upside of about 9.6% from the current price, but the continued cautious stance reflects the broker's wait-and-see approach to the stock. Sanofi also fell by 1.63% at the same time, with no direct sector link to clarify Eurofins' movement. The downward trend follows a difficult April, after first-quarter accounts were poorly received, already causing a drop of more than 10% at the time of publication.
Eurofins Scientific Below MM50 and MM200, but RSI Remains Neutral
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Over three months, Eurofins Scientific has declined by 10.3%, while the annual performance remains positive at 8.17%. The stock is now trading below the MM50 at €62.50 (a gap of -2.18%) and the MM200 at €63.41 (a gap of -3.58%), while slightly above the MM20 at €60.19. This configuration places the stock in a transition zone, with an RSI at 55 indicating a still neutral momentum despite the day's decline. The support threshold identified at €57.54 remains the next technical milestone, a level approached at the beginning of May during the dip to €57.34. However, the resistance at €69.84 appears distant, more than 14% above the current price. In the absence of an upcoming financial calendar, the stock's trajectory will depend on its ability to stabilize above €60.
SectorSanté · Vaccins et laboratoires de recherche›Services médicaux
Context
Period
Period: 1T2026
Key reported figures
Revenue: 1789M€
Guidance from the release
Eurofins a rencontré des vents contraires importants et temporaires.
Malgré une croissance organique modérée, la rentabilité et les marges progressent.
Risks mentioned
Baisse de la demande en raison de conditions climatiques défavorables en Amérique du Nord.
Rationalisation des contrats dans les diagnostics cliniques en Espagne et en Italie.
Opportunities identified
Lancement de nouveaux contrats renforçant notre portefeuille BioPharma.
Initiatives de digitalisation et amélioration du réseau de laboratoires.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.